VITEK 2 与 VITEK 2 Compact 系统对肠杆菌目普拉佐米星药敏试验的性能评估
本研究在四个外部站点评估 VITEK 2 药敏试验检测肠杆菌目普拉佐米星的性能,共测试 979 株分离株,并与 CLSI 肉汤微量稀释法比对。按 ISO 标准 EA 为 97.8%,按 FDA 标准 EA 为 98.7%、CA 为 99.4%、ME 为 0.1%,无 VME。
要点
- VITEK 2 普拉佐米星药敏试验与 CLSI 肉汤微量稀释法具有高度一致性。
- 按 FDA 折点分析,ME 为 0.1%,未出现 VME。
- 重现性和质控结果均满足 ISO 和 FDA 的 ≥95% 标准。
核心结论
- VITEK 2 普拉佐米星药敏试验可作为肠杆菌目 MIC 测定的自动化替代方法,性能符合 ISO 和 FDA 标准。
研究设计与样本
- 在四个外部站点开展的多中心临床研究,遵循 FDA 和 ISO 指南,包含临床、挑战、质量和重现性研究,共测试 979 株肠杆菌目分离株。
主要发现
- 按 ISO 标准,基本一致性(EA)为 97.8%。
- 按 FDA 折点分析,EA 为 98.7%,分类一致性(CA)为 99.4%,重大错误(ME)为 0.1%,无极重大错误(VME)。
- 除大肠埃希菌外,VITEK 2 普拉佐米星 MIC 结果与 CLSI BMD 参考方法完全一致;大肠埃希菌的 MIC 倾向于完全一致或至少低一个倍比稀释度。
- 肺炎克雷伯菌、大肠埃希菌和粘质沙雷菌的趋势≥30%,已在美国标签中以注释形式说明。
关键数值与推荐
- FDA 折点:≤2 为敏感(S),4 为中介(I),≥8 为耐药(R)。
- 重现性≥95%,质控菌株质控结果在可接受范围内的比例≥95%。
临床怎么用
- 临床实验室可采用 VITEK 2 或 VITEK 2 Compact 系统对肠杆菌目进行普拉佐米星药敏试验,但需注意大肠埃希菌的 MIC 可能偏低一个稀释度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The objective of the present study was to evaluate the VITEK 2 antimicrobial susceptibility test (AST) for Gram-negative (GN) plazomicin performance using the VITEK 2 and VITEK 2 Compact Systems in clinical settings and to demonstrate its equivalence to the Clinical and Laboratory Standards Institute (CLSI) broth microdilution (BMD) technique. The clinical study conducted at four external sites followed the requirements detailed in the US Food and Drug Administration (FDA) and International Standards Organization (ISO) guidance documents and included clinical, challenge, quality, and reproducibility studies. In this multisite study, a total of 979 Enterobacterales isolates were tested. The VITEK 2 card minimum inhibitory concentration (MIC) results were compared with the reference BMD MIC results. The performance following ISO criteria indicated Essential Agreement (EA) = 97.8% and showed that VITEK 2 plazomicin MIC results for Enterobacterales tend to be in exact agreement when compared with the CLSI BMD reference method, except for Escherichia coli, when MICs tend to be in exact agreement or at least one doubling dilution lower. The analysis was also performed following the FDA criteria using the breakpoints defined by the FDA: ≤2 susceptible (S), 4 intermediate (I), and ≥8 resistant (R) for Enterobacterales. The analysis showed the following performance: EA = 98.7%, category agreement (CA) = 99.4%, and major errors (ME) = 0.1%, with no very major errors (VME) present. There are three species, Klebsiella pneumoniae, Escherichia coli, and Serratia marcescens, for which the trend is ≥ 30% and therefore addressed as a note in the US label. The plazomicin test met the ISO and FDA criteria of ≥95% reproducibility and ≥95% quality control (QC) results within acceptable ranges for QC organisms.IMPORTANCEThe VITEK 2 AST-GN plazomicin test is a new, automated alternative to the BMD reference method for determining minimum inhibitory concentrations (MIC) of Enterobacterales, expanding the range of automatic AST testing.
引用
- Csiki-Fejer E, Traczewski M, Procop GW, et al. Performance evaluation of plazomicin susceptibility testing of Enterobacterales on VITEK 2 and VITEK 2 Compact Systems. J Clin Microbiol. 2025. PMID: 40748078. doi:10.1128/jcm.00449-25
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。